Please provide your email address to receive an email when new articles are posted on . In a second phase 3 registration trial, Nyxol helped reverse pharmacologically induced mydriasis at 90 minutes, ...

Dublin, Dec. 30, 2020 (GLOBE NEWSWIRE) -- The "Mydriasis - Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. The 'Mydriasis ...

Credit: Shutterstock. Ryzumvi is a preservation-free eye drop formulation of phentolamine mesylate, an alpha adrenergic blocker. The Food and Drug Administration (FDA) has approved Ryzumvi™ ...

Please provide your email address to receive an email when new articles are posted on . Nyxol, an alpha 1/2 antagonist eye drop, helped reverse the effects of pharmacologically induced mydriasis in ...

FARMINGTON HILLS, Mich., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small ...

A 3-year-old girl with an unremarkable medical history suddenly developed dilated pupils and trouble walking, according to a case report in JAMA Ophthalmology. The child was brought in to the ...

The FDA has approved phentolamine ophthalmic solution (Ryzumvi) 0.75% for treatment-induced mydriasis, Viatris and Ocuphire Pharma announced. The approval stipulates use of the eye drops to manage ...

Credit: Getty Images. MydCombi is a combination of tropicamide, an anticholinergic, and phenylephrine hydrochloride, an alpha-1 adrenergic receptor agonist. The Food and Drug Administration (FDA) has ...

The differential diagnosis of mydriasis that is greater in bright light includes third nerve palsy, Adie's pupil, traumatic mydriasis, and pharmacologic mydriasis. In this case, third nerve palsy was ...

To describe two cases of stereotyped, intermittent, neurologically isolated, unilateral mydriasis in patients with a history of acquired internal carotid artery (ICA) occlusive disease on the ...

Vindesine (VDS), one of the vinca alkaloids, is widely used as an antineoplastic agent. Possible target sites are microtubules and tubulins in cancer cells. As the adverse effects of VDS, ...